Total number of voting rights and share capital in Bavarian Nordic A/S


An increase of the share capital by Bavarian Nordic A/S was effected on 2
February 2010 by subscription of 3,960,307 shares, with a nominal value of DKK
10 each.

Pursuant to section 6 of Executive Order no. 1273 of 16 December 2008 on
Issuers' Disclosure Obligations, it is hereby announced that the total nominal
value of Bavarian Nordic A/S' share capital is DKK 119,120,520 at the end of
February 2010, which is made up of 11,912,052 shares of a nominal value of DKK
10 each corresponding to 11,912,052 votes.


Contact
Anders Hedegaard, President & CEO. Phone +45 23 20 30 64

Forward-looking statements
This announcement includes "forward-looking statements" that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. We undertake no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances after the date made, except as required by law.

About Bavarian Nordic
Bavarian Nordic A/S is a leading industrial biotechnology company developing and
producing novel vaccines for the treatment and prevention of life-threatening
diseases with a large unmet medical need. The company's pipeline is focused in
the three areas; biodefence, cancer and infectious diseases, and includes seven
development programmes. Two programmes are under preparation for Phase III:
IMVAMUNE®, a third-generation smallpox vaccine is being developed under a
contract with the US government, and PROSTVAC(TM), a therapeutic vaccine for
advanced prostate cancer is being developed under a collaboration agreement with
the National Cancer Institute.

Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.

For more information please visit www.bavarian-nordic.com
<http://www.bavarian-nordic.com/>





[HUG#1388699]


Attachments

2010-14-uk.pdf